ZA200507067B - Antibodies against human IL-21 receptor and uses therefor - Google Patents

Antibodies against human IL-21 receptor and uses therefor

Info

Publication number
ZA200507067B
ZA200507067B ZA200507067A ZA200507067A ZA200507067B ZA 200507067 B ZA200507067 B ZA 200507067B ZA 200507067 A ZA200507067 A ZA 200507067A ZA 200507067 A ZA200507067 A ZA 200507067A ZA 200507067 B ZA200507067 B ZA 200507067B
Authority
ZA
South Africa
Prior art keywords
receptor
antibodies against
against human
uses therefor
therefor
Prior art date
Application number
ZA200507067A
Other languages
English (en)
Inventor
Deborah A Young
Matthew J Whitters
Valge-Archer Viia
Collins Mary
Williams Andrew James
Witek Joanne
Original Assignee
Wyeth Corp
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33029874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200507067(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Cambridge Antibody Tech filed Critical Wyeth Corp
Publication of ZA200507067B publication Critical patent/ZA200507067B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200507067A 2003-03-14 2005-09-02 Antibodies against human IL-21 receptor and uses therefor ZA200507067B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45433603P 2003-03-14 2003-03-14

Publications (1)

Publication Number Publication Date
ZA200507067B true ZA200507067B (en) 2006-12-27

Family

ID=33029874

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200507067A ZA200507067B (en) 2003-03-14 2005-09-02 Antibodies against human IL-21 receptor and uses therefor

Country Status (20)

Country Link
US (2) US7495085B2 (no)
EP (2) EP1603949B9 (no)
JP (1) JP4914209B2 (no)
KR (1) KR20050119120A (no)
CN (2) CN102040662A (no)
AR (1) AR043616A1 (no)
AT (1) ATE456581T1 (no)
AU (1) AU2004221876B2 (no)
BR (1) BRPI0408315A (no)
CA (1) CA2518371A1 (no)
CL (1) CL2004000534A1 (no)
CO (1) CO5660297A2 (no)
DE (1) DE602004025332D1 (no)
ES (1) ES2340280T3 (no)
MX (1) MXPA05009556A (no)
NO (1) NO20054170L (no)
NZ (1) NZ542306A (no)
RU (1) RU2005131852A (no)
WO (1) WO2004083249A2 (no)
ZA (1) ZA200507067B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
ZA200500480B (en) 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
BRPI0408523A (pt) * 2003-03-21 2006-03-21 Wyeth Corp métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
CN1980698A (zh) * 2004-05-19 2007-06-13 惠氏公司 免疫球蛋白产生和特应性疾病的调节
KR20070057789A (ko) * 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
EP2368995A3 (en) 2005-03-25 2012-01-18 National Research Council of Canada Method for isolation of soluble polypeptides
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
AU2006341398B9 (en) * 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
AU2006323315B2 (en) * 2005-12-09 2014-02-20 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007109749A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
US20090022727A1 (en) * 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
SI2167540T1 (en) 2007-06-29 2018-05-31 F. Hoffmann-La Roche Ag A mutant heavy chain that enables improved production of immunoglobulins
US20110212100A1 (en) * 2007-08-15 2011-09-01 Tracy Keller Methods for modulating development and expansion of il-17 expressing cells
DK2217268T3 (en) * 2007-12-07 2016-08-15 Zymogenetics Inc MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
WO2009111889A1 (en) * 2008-03-13 2009-09-17 The Hospital For Sick Children Lymphocyte control of obesity and insulin resistance
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
WO2009143526A1 (en) * 2008-05-23 2009-11-26 Wyeth Methods of treatment utilizing binding proteins of the interleukin-21 receptor
JP2012504939A (ja) * 2008-09-23 2012-03-01 ワイス・エルエルシー 架橋結合タンパク質による活性化シグナルの産生を予測するための方法
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US20130224109A1 (en) * 2010-07-20 2013-08-29 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
DK2646466T3 (en) 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
CA2834619A1 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
CN105229033B (zh) 2013-03-14 2019-04-23 拜尔健康护理有限责任公司 针对与肝素复合的抗凝血酶β的单克隆抗体
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
JP2018532801A (ja) * 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
JP7010833B2 (ja) * 2016-03-31 2022-02-10 イーライ リリー アンド カンパニー Ｉｌ－２１抗体及びその使用
JP6989138B2 (ja) * 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体及びその使用
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019052562A1 (zh) * 2017-09-15 2019-03-21 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
MX2022000191A (es) * 2019-06-26 2022-05-06 Univ Johns Hopkins Metodos y materiales para la expansión dirigida de celulas t reguladoras.
WO2021129656A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2023023150A2 (en) * 2021-08-18 2023-02-23 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
BRPI9715219B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
EP0812913A3 (en) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
AUPO224696A0 (en) 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
EP1005552A1 (en) 1997-01-16 2000-06-07 Genetics Institute, Inc. Member of the hematopoietin receptor superfamily
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US20010025022A1 (en) 1997-11-26 2001-09-27 Kikly Kristine Kay Hnovilr
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP1088831A4 (en) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd HEMOPOIETIN RECEPTOR PROTEINS
WO2000008152A1 (en) * 1998-08-04 2000-02-17 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
ES2329741T3 (es) 1998-09-23 2009-11-30 Zymogenetics, Inc. Receptor de citoquinas zalpha11.
US6803451B2 (en) * 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6355788B1 (en) * 1998-10-15 2002-03-12 Zymogenetics, Inc. Follistatin-related protein zfsta2
WO2000027882A1 (en) 1998-11-06 2000-05-18 Smithkline Beecham Corporation Hnovilr
HU229148B1 (en) 1999-03-09 2013-09-30 Zymogenetics Inc Seattle Human cytokine as ligand of the zalpha receptor and uses thereof
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CA2796140A1 (en) 1999-03-25 2000-09-28 Jochen Salfeld Human antibodies that bind human il-12 and methods for producing
US20020090680A1 (en) 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
CA2392109A1 (en) 1999-11-18 2001-05-25 Schering Corporation Mammalian receptor proteins; related reagents and methods
JP2003520852A (ja) 2000-01-27 2003-07-08 アメリカン・サイアナミド・カンパニー α−スルホニルヒドロキサム酸誘導体を製造する方法
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
PT1353953E (pt) 2000-05-11 2007-02-28 Genetics Inst Llc Mu-1, membro da família dos receptores de citocina
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
NZ532021A (en) * 2001-10-04 2008-05-30 Genetics Inst Llc Methods and compositions for modulating interleukin-21 receptor activity
CA2465156C (en) 2001-11-05 2011-10-18 Zymogenetics, Inc. Il-21 antagonists
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
ZA200500480B (en) 2002-07-15 2006-10-25 Wyeth Corp Methods and compositions for modulating T helper (TH) cell development and function
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
BRPI0408523A (pt) 2003-03-21 2006-03-21 Wyeth Corp métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura
CN1980698A (zh) 2004-05-19 2007-06-13 惠氏公司 免疫球蛋白产生和特应性疾病的调节
KR20070057789A (ko) 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)

Also Published As

Publication number Publication date
NZ542306A (en) 2008-04-30
NO20054170L (no) 2005-12-05
AU2004221876B2 (en) 2011-05-26
US20040265960A1 (en) 2004-12-30
NO20054170D0 (no) 2005-09-07
CL2004000534A1 (es) 2005-03-04
US7495085B2 (en) 2009-02-24
AR043616A1 (es) 2005-08-03
RU2005131852A (ru) 2006-04-20
WO2004083249A2 (en) 2004-09-30
CN1777621A (zh) 2006-05-24
EP1603949B9 (en) 2011-02-02
JP4914209B2 (ja) 2012-04-11
CN102040662A (zh) 2011-05-04
ATE456581T1 (de) 2010-02-15
JP2007525159A (ja) 2007-09-06
DE602004025332D1 (de) 2010-03-18
EP1603949A2 (en) 2005-12-14
EP1603949B8 (en) 2010-03-10
EP1603949B1 (en) 2010-01-27
ES2340280T3 (es) 2010-06-01
CO5660297A2 (es) 2006-07-31
EP2184298A1 (en) 2010-05-12
KR20050119120A (ko) 2005-12-20
AU2004221876A1 (en) 2004-09-30
MXPA05009556A (es) 2005-11-16
US8143385B2 (en) 2012-03-27
CA2518371A1 (en) 2004-09-30
WO2004083249A3 (en) 2004-12-09
US20100297151A1 (en) 2010-11-25
BRPI0408315A (pt) 2006-03-07

Similar Documents

Publication Publication Date Title
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
ME02245B (me) Anti-cd38 humana antitjela i njihove upotrebe
HK1205748A1 (en) Therapeutic epitopes and uses thereof
SI2511297T1 (sl) Proti -CD38 humana protitelesa in njihova uporaba
IL179476A0 (en) Antibodies against human interleukin-13 and uses therefor
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
IL173273A0 (en) Modified human igf-1r antibodies
PL2272873T3 (pl) Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
IL168304A (en) Human monoclonal antibodies against cd25
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
ZA200606319B (en) Anti-CD38 human antibodies and uses therefor
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
IL172511A0 (en) Specific human antibodies
IL172510A0 (en) Antibodies and uses thereof
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) ANTIBODY AND ITS USE
IL166063A0 (en) Antibodies and uses thereof
AU2003287016A8 (en) Human sarcoma-associated antigens
EP1627888A4 (en) ANTIBODY AND ITS USE
GB0325391D0 (en) Human monoclonal antibodies
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
IL174076A0 (en) Antibodies against interleukin-1 receptor and uses thereof
GB0227080D0 (en) Antibodies and uses thereof